Drug intelligence / Profile preview

TRIV-920

Development stage: Preclinical
Lead developer: Triveni BIO
Modality: Antibody-Based Therapeutics
Administration: Parenteral

Overview

TRIV-920 is a dual inhibitor antibody targeting trypsin-1 and trypsin-2, developed by Triveni Bio for the treatment of hereditary pancreatitis. It acts as an anti-inflammatory agent by inhibiting serine proteases (trypsins), which are implicated in the pathogenesis of pancreatitis and other digestive system disorders. The drug is currently in the discovery/preclinical stage, with no clinical trial data reported as of June 2025. Its primary indication is hereditary pancreatitis[1][2][3].

Other names: TRIV 920TRIV920TRIV-920

Targets

PRSS2 (Trypsin-2)

Beyond the preview

Go deeper on TRIV-920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIV-920.

Explore the full profile